Comparison of the patient characteristics, treatment strategies, and survival outcomes from the key observational studies of LT
| . | . | All patients . | Induction chemotherapy . | HCT . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study* . | Preceeding MPN . | n . | Median OS, mo . | n . | Favorable response, n (%) . | Median OS, mo . | n . | Pretreated with induction, % . | In CR/CRi/cMPN at transplant, % . | 2-y OS, % . |
| 1 | PMF, PPV-MF, PET-MF | 91 | 2.6 | 24 | 10 (42) | 3.9 | 0 | — | — | — |
| 2 | all Ph-MPNs† | 74 | 5 | 41 | 18 (46) | Not reported | 8‡ | 62.5 | 75 | 73 |
| 4 | all Ph-MPNs† | 23 | 4.6 | 20 | 12 (60) | 6 | 3 | 100 | Not reported | Not reported |
| 9 | ET, PV, PMF | 13 | Not reported | 10 | 6 (60) | Not reported | 8 | 100 | 62.5 | 75§ |
| Transplant-focused studies | ||||||||||
| 7 | PMF, PPV-MF, PET-MF | — | — | — | — | — | 14 | 93 | 43 | 49 |
| 8 | PMF, PPV-MF, PET-MF | — | — | — | — | — | 5 | 20 | ≤20 | 53 |
| Present study | all Ph-MPNs† | 75 | 6.5 | 38 | 29 (76) | 9.2 | 17 | 94 | 100 | 47 |
| . | . | All patients . | Induction chemotherapy . | HCT . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study* . | Preceeding MPN . | n . | Median OS, mo . | n . | Favorable response, n (%) . | Median OS, mo . | n . | Pretreated with induction, % . | In CR/CRi/cMPN at transplant, % . | 2-y OS, % . |
| 1 | PMF, PPV-MF, PET-MF | 91 | 2.6 | 24 | 10 (42) | 3.9 | 0 | — | — | — |
| 2 | all Ph-MPNs† | 74 | 5 | 41 | 18 (46) | Not reported | 8‡ | 62.5 | 75 | 73 |
| 4 | all Ph-MPNs† | 23 | 4.6 | 20 | 12 (60) | 6 | 3 | 100 | Not reported | Not reported |
| 9 | ET, PV, PMF | 13 | Not reported | 10 | 6 (60) | Not reported | 8 | 100 | 62.5 | 75§ |
| Transplant-focused studies | ||||||||||
| 7 | PMF, PPV-MF, PET-MF | — | — | — | — | — | 14 | 93 | 43 | 49 |
| 8 | PMF, PPV-MF, PET-MF | — | — | — | — | — | 5 | 20 | ≤20 | 53 |
| Present study | all Ph-MPNs† | 75 | 6.5 | 38 | 29 (76) | 9.2 | 17 | 94 | 100 | 47 |
Reference 6 not included, as no survival analysis was reported.
All Ph-MPNs = PV, ET, PMF, PPV-MF, PET-MF, MPN-U.
Survival data only provided for 8 of 11 patients that underwent HCT; all 8 had either primary or secondary myelofibrosis.
Value is 2-y progression-free survival (OS not provided).
PET-MF, postessential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; PPV-MF, postpolycythemia myelofibrosis.